Use of delta opioid receptor antagonists to treat immunoregulatory disorders
AssigneesMinneapolis Medical Research Foundation, Inc., Regents of the University of Minnesota
InventorsPhilip S. Portoghese, Burt M. Sharp, Kristin M. Linner
Life of this patent
Estimating the term…
Abstract
A therapeutic method is provided to elevate a depressed mammalian autologous mixed lymphocyte response and to alleviate the diseases associated therewith by the administration of an effective amount of certain selective delta opioid receptor antagonists to a mammal such as a human patient in need of such treatment.
Claims22
A therapeutic method for treating an immunoregulatory disease selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosis, Sjogren's Syndrome, multiple sclerosis, chronic lymphocytic leukemia, Type I diabetes, Epstein-Barr virus and AIDS characterized by a depressed autologous mixed lymphocyte response comprising administering to a mammal in need of such treatment an amount of a compound of the Formula I:
- ##STR9## wherein R.sup.1 is (C.sub.1 -C.sub.5)alkyl, C.sub.3 -C.sub.6 (cycloalkyl)alkyl, C.sub.5 -C.sub.7 (cycloalkenyl)alkyl, aryl, aralkyl, trans(C.sub.4 -C.sub.5)-alkenyl, allyl or furan-2-ylalkyl, R.sup.2 is H, OH or O.sub.2 C(C.sub.1 -C.sub.5)alkyl;
- R.sup.3 is H, (C.sub.1 -C.sub.5)alkyl;
- or ((C.sub.1 -C.sub.5)alkyl)-CO;
- R.sup.4 and R.sup.5 are individually H, F, Cl, Br, NCS, NO.sub.2, NH.sub.2, (C.sub.1 -C.sub.5)alkyl or (C.sub.1 -C.sub.5)alkoxy, or together are benzo;
- and X is O, S or NY, wherein Y is H, (C.sub.1 -C.sub.5)alkyl or benzyl;
- and the pharmaceutically acceptable salts thereof;
- wherein said amount is effective to elevate the AMLR of said mammal.
Dependencies are inferred from the claim text.